1. Home
  2. HWH vs BGLC Comparison

HWH vs BGLC Comparison

Compare HWH & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HWH International Inc.

HWH

HWH International Inc.

HOLD

Current Price

$1.38

Market Cap

8.5M

Sector

Health Care

ML Signal

HOLD

Logo BioNexus Gene Lab Corp

BGLC

BioNexus Gene Lab Corp

HOLD

Current Price

$2.25

Market Cap

10.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HWH
BGLC
Founded
2021
2017
Country
United States
Malaysia
Employees
N/A
N/A
Industry
Other Pharmaceuticals
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.5M
10.1M
IPO Year
2022
2019

Fundamental Metrics

Financial Performance
Metric
HWH
BGLC
Price
$1.38
$2.25
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
21.3K
7.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
45.78
EPS
N/A
N/A
Revenue
N/A
$9,510,646.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.90
$0.23
52 Week High
$7.77
$15.19

Technical Indicators

Market Signals
Indicator
HWH
BGLC
Relative Strength Index (RSI) 47.97 39.25
Support Level $1.33 $2.12
Resistance Level $1.50 $2.73
Average True Range (ATR) 0.12 0.13
MACD 0.02 0.01
Stochastic Oscillator 67.07 21.31

Price Performance

Historical Comparison
HWH
BGLC

About HWH HWH International Inc.

HWH International Inc is and its consolidated subsidiaries operate a food and beverage business in Singapore and South Korea. The F&B business operates four cafes, two of which are located in South Korea and two in Singapore, as well as an online healthy food store, serving customers in Singapore.

About BGLC BioNexus Gene Lab Corp

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

Share on Social Networks: